Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ELCC 2021 | Update from a phase 1 study of AMG 757 in SCLC

Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, shares an update on a Phase I study of AMG 757 (NCT03319940) in patients with small cell lung cancer (SCLC). AMG 757 is a bispecific T-cell engager (BiTE) which simultaneously binds to delta-like ligand 3 (DLL3) on SCLC cells and CD3 on T-cells. 52 patients were enrolled on the study. 79% of patients reported treatment-related adverse events (AEs) of which 8% were grade 4 or above. Cytokine release syndrome occurred in 44% of patients. 14% of patients achieved a partial response (PR) according to modified RECIST 1.1 criteria and 24% of patients achieved stable disease. The median time to response was 1.8 months and the estimated duration of response was over six months in 83% of patients with a confirmed PR. This video was recorded at the virtual European Lung Cancer Congress (ELCC) 2021.